
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci is demonstrating strong potential for success in the biopharmaceutical industry through its data-driven approach, focus on endometriosis, and partnerships with other companies. The promising results of ABS-201 in preclinical studies and its licensing to Hope Medicine, along with the evidence of prolactin's role in endometriosis and the endorsement of its CEO's vision of merging human ingenuity and machine intelligence, indicate a positive outlook for the company's future. However, the success of their lead product in clinical trials remains uncertain.
Bears say
Absci is a promising company in the biotech space with a unique approach to drug discovery, but their reliance on third-party suppliers and potential competition in the market make their future unpredictable. Additionally, the projected peak sales for their lead product may not meet investors' expectations. The potential delays in clinical trials also pose a risk to the company's growth and profitability.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares